Precision medicine in clinical practice.
In reports of clinical efficacies of new therapies in prospective randomized controlled trials, evidence showing proportion of respondents who meet the minimum clinically important difference in prespecified clinical end points are often not presented. Such reporting deficiency negatively impacts precision medicine practice in clinics. As all patient-centric decisions are binary, patients must be understood as individuals and not group averages. At any visit, a clinician must decide whether to prescribe or not to prescribe a unique therapy to a unique patient at that unique time. I submit my perspective here that reports of clinical evidence of drug efficacy must routinely include data and summary statistics from dichotomization of clinical end points at the prespecified minimum clinically important difference or higher cutoffs to inform personalized treatment decisions in clinics.